NCT04655898

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

A Phase 1, Single-Center, Open-label Study to Evaluate the Metabolism and Exception of [14C]-CC-90001 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Celgene · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the study with a goal of 6 subjects being eligible for analysis.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	[14C]CC-90001	Oral

Timeline

• Start date: 2020-12-16
• Primary completion: 2021-03-11
• Completion: 2021-03-11
• First posted: 2020-12-07
• Last updated: 2021-06-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study